IDH1 mutation detection by droplet digital PCR in glioma
Metrics: PDF 1285 views | HTML 1718 views | ?
Jing Wang1,2, Yi-ying Zhao1, Jian-feng Li3, Cheng-cheng Guo1, Fu-rong Chen1, Hong-kai Su1, Hua-fu Zhao2, Ya-kang Long4, Jian-yong Shao4, Shing-shun Tony To2, Zhong-ping Chen1
1Department of Neurosurgery/Neuro-oncology, Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China
2Department of Health Technology and Informatics, The Hong Kong Polytechnic University, Hung Hom, Hong Kong, China
3Department of Neurosurgery, Affiliated Shantou Hospital of Sun Yat-Sen University, Shantou, China
4Department of Molecular Diagnosis, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China
Shing-shun Tony To, e-mail: firstname.lastname@example.org
Zhong-ping Chen, e-mail: email@example.com
Keywords: glioma, isocitrate dehydrogenase (IDH), droplet digital PCR (ddPCR), quantitative real-time PCR (qRT-PCR), sensitivity
Received: July 27, 2015 Accepted: October 02, 2015 Published: October 14, 2015
Glioma is the most frequent central nervous system tumor in adults. The overall survival of glioma patients is disappointing, mostly due to the poor prognosis of glioblastoma (Grade IV glioma). Isocitrate dehydrogenase (IDH) is a key factor in metabolism and catalyzes the oxidative decarboxylation of isocitrate. Mutations in IDH genes are observed in over 70% of low-grade gliomas and some cases of glioblastoma. As the most frequent mutation, IDH1(R132H) has been served as a predictive marker of glioma patients. The recently developed droplet digital PCR (ddPCR) technique generates a large amount of nanoliter-sized droplets, each of which carries out a PCR reaction on one template. Therefore, ddPCR provides high precision and absolute quantification of the nucleic acid target, with wide applications for both research and clinical diagnosis. In the current study, we collected 62 glioma tissue samples (Grade II to IV) and detected IDH1 mutations by Sanger direct sequencing, ddPCR, and quantitative real-time PCR (qRT-PCR). With the results from Sanger direct sequencing as the standard, the characteristics of ddPCR were compared with qRT-PCR. The data indicated that ddPCR was much more sensitive and much easier to interpret than qRT-PCR. Thus, we demonstrated that ddPCR is a reliable and sensitive method for screening the IDH mutation. Therefore, ddPCR is able to applied clinically in predicting patient prognosis and selecting effective therapeutic strategies. Our data also supported that the prognosis of Grade II and III glioma was better in patients with an IDH mutation than in those without mutation.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.